What is Candel Therapeutics, Inc.'s gain/loss on asset sales?

Candel Therapeutics, Inc. (CADL) reported gain/loss on asset sales of -$300K in Q3 2025.

What does gain/loss on asset sales mean?

Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.

Candel Therapeutics, Inc. CADL Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

Immix Biopharma, Inc.IMMX

-$34.15K—

ImmunomeIMNM

-$79K—

Enliven TherapeuticsELVN

-$26.5K-864%

Other financials

Income statement

See full

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

See full

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

See full

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

See full

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

See full

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

See full

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed November 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Candel Therapeutics, Inc.'s gain/loss on asset sales?: Candel Therapeutics, Inc. (CADL) reported gain/loss on asset sales of -$300K in Q3 2025.
What does gain/loss on asset sales mean?: Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.